65,437 trials
Non-Small Cell Lung Cancer
Primary: Survival Without Grade 3 or 4 Toxicity — 3.2; 0.7 months — p=<0.001
End Stage Renal Disease
Primary: Number of Steps Completed in Transplant Process — 1.0; 2.8 steps per participant
Hypovolemic Shock · Hemorrhage
Primary: Extreme Adverse Outcomes (EAO) - a Combined Outcome of Maternal Mortality or Severe Morbidity (Cardiac,Respiratory, Renal or Cerebral Dysfunction) — 27; 11 participants…
Partial Epilepsies · Partial Onset Seizures
Primary: Number of Subjects With at Least One Adverse Event During This Open-label Extension Study (Maximum Study Duration 2 Years) — 93 subjects
Hypercholesteremia
Primary: Percent Change From Baseline (Before the Start of Rosuvastatin Treatment) to Week 76 in the Plaque Volume (PV) — 14.1 Percent Change
Hepatocellular Carcinoma
Primary: Number of Participants Who Remained Free of Progression at the 27th Week. — 21 participants — p=0.0006
Adult Acute Basophilic Leukemia · Adult Acute Eosinophilic Leukemia · Adult Acute Megakaryoblastic Leukemia (M7)
Primary: Number of Participants With Complete Response — 61; 9 Participants
Hemophilia A
Primary: Factor VIII Inhibitor Development — 29.1 percentage
Anemia · Neoplasms
Primary: Number of Participants With at Least 1 Clinically Relevant and Objectively Confirmed Thrombovascular Event From Randomization Through Week 16 — 5; 10 particpants — p=0.248
Parkinson Disease
Primary: Percentage of Patients With Adverse Events, Adverse Drug Reactions, Serious Adverse Events — 85.3; 83.7; 79.9; 52.7 Percentage of participants
Advanced Cancer
Primary: Percent of Participants With a Serious Drug-related Adverse Event (AE) — 7.7; 0; 0; 0 percent of participants
Maternal Obesity · Gestational Weight Gain · Obstetric Complications
Primary: Cesarean Section
Major Depressive Disorder
Primary: Change From Augmentation Baseline for Non-Remitters in Montgomery-Ǻsberg Depression Rating Scale (MADRS) Total Score at Week 6 - Last Observation Carried Forward (LOCF)…
Healthy
Primary: High VAS - Emax (mm) — 23.1; 30.6; 62.5; 81.4 mm — p=<0.001
Gastrointestinal Cancer
Primary: Number of Participants With Overall Response — 3; 12 participants